NARI continues to gain from its expanded product portfolio. However, continued loss at the operating level raises concern.
Vous n'êtes pas connecté
FMS continues to gain traction through its broad dialysis product and service portfolio. Ongoing macro challenges raise concerns.
NARI continues to gain from its expanded product portfolio. However, continued loss at the operating level raises concern.
PacBio's (PACB) strong product demand and continued focus on R&D raise optimism about the stock.
RVTY's strong product portfolio raises optimism about the stock.
FMS introduces NxStage VersiHD with GuideMe Software to simplify home dialysis and grow its patient base in the United States.
FMS introduces NxStage VersiHD with GuideMe Software to simplify home dialysis and grow its patient base in the United States.
CAH gains from a solid pharmaceutical segment and a diversified product portfolio. However, regulatory setbacks are a concern.
REG is set to gain from its ownership of premium shopping centers and a solid balance sheet. However, rising e-commerce adoption and high interest...
Investors remain optimistic about Patterson Companies on the back of its broad product line.
Investors remain optimistic about Patterson Companies on the back of its broad product line.
ARAY's solid product demand and revenue growth raise optimism about the stock.